# US 2024/0189486 A1 · Antimicrobial cationic peptoid and n-subtituted peptidic copolymers, preparation and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189486 A1
- Document ID: US20240189486A1
- Status: Published application
- Kind: A1
- Application number: 18/546,945
- Filed: 2022-02-16
- Published: 2024-06-13
- Earliest claimed: 2021-02-17
- Assignees: Universite De Bordeaux; Centre National De La Recherche Scientifique; Institut Polytechnique De Bordeaux; Universite Paul Sabatier Toulouse III; Institut Pasteur
- Applicants: Université de Bordeaux; Centre National de la Recherche Scientifique; Institut Polytechnique de Bordeaux; Université Paul Sabatier Toulouse III; Institut Pasteur
- Inventors: Colin BONDUELLE; Pierre VERHAEGHE; Bruno DUPUY; Pedro SALAS-AMBROSIO; Antoine TRONNET
- Web page: https://patentgrep.com/patent/US20240189486A1

## CPC

- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/22: Polypeptides or derivatives thereof {, e.g. degradation products}
- A61L 27/34: Macromolecular materials
- A61L 29/085: {Macromolecular materials}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 31/10: Macromolecular materials
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 31/04: Antibacterial agents
- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K 14/001: {by chemical synthesis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- A61L 2430/16: for reconstruction of eye parts, e.g. intraocular lens, cornea
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides cationic peptoid/N-substituted peptidic copolymers, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful for the treatment of microbial infections.

## Claims

### Claim 1

Process for the preparation of cationic peptoid/N-substituted peptidic copolymers comprising-:
A) at least one step of reacting in a polar solvent:
(i) at least a first N-carboxyanhydride monomer having the structure (I):
wherein
R1 independently represents a cyclic or acyclic, substituted or unsubstituted, linear or branched C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12heteroalkyl, C2-12heteroalkenyl or C2-12heteroalkynyl group; each of the foregoing alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl group, optionally bearing one or more substituents selected from F; Cl; Br; I; —NO2; —CN; —CF3; —CH2CF3; CHCl2; or -GRA1 wherein G is —O—, —S—, —NRB1—, —C(═O)—, —S(═O)—, —SO2—, —C(═O)O—, —C(═O)NRB1—, —OC(═O)—, —NRB1C(═O)—, wherein each occurrence of RA1 and RB1 independently represents hydrogen, or a C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12haloalkyl, C2-12haloalkenyl, C2-12haloalkynyl, C1-12heteroalkyl, C2-12heteroalkenyl or C2-12heteroalkynyl group; and
R2 independently represents H, a cyclic or acyclic, substituted or unsubstituted, linear or branched C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12heteroalkyl, C2-12heteroalkenyl, C2-12heteroalkynyl, substituted or unsubstituted C6-10aryl or C4-10heteroaryl group; —ORA2; —C(═O)RA2; or —SRA2; wherein each occurrence of RA2 independently represents hydrogen or a cyclic or acyclic, substituted or unsubstituted, linear or branched C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12heteroalkyl, C2-12heteroalkenyl, C2-12heteroalkynyl, C6-10aryl or C4-10heteroaryl group; wherein each of the foregoing alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl or heteroaryl group may optionally bear one or more substitutents selected from F; Cl; Br; I; —NO2; —CN; —CF3; —CH2CF3; CHCl2; or -GRB2 wherein G is —O—, —S—, —NRC2—, —C(═O)—, —S(═O)—, —SO2—, —C(═O)O—, —C(═O)NRC2—, —OC(═O), —NRC2C(═O)—, wherein each occurrence of RB2 and RC2 independently represents independently represents hydrogen, or a C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12haloalkyl, C2-12haloalkenyl, C2-12haloalkynyl, C1-12heteroalkyl, C2-12heteroalkenyl, C2-12heteroalkynyl, C6-10aryl or C4-10heteroaryl group;
wherein at least one of R1 or R2 bears at least one cationic moiety or protected form thereof;
(i) at least a second N-carboxyanhydride monomer having the structure (II):
wherein
R3 independently represents a cyclic or acyclic, substituted or unsubstituted, linear or branched C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12heteroalkyl, C2-12heteroalkenyl, or C2-12heteroalkynyl; each of the foregoing alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl or heteroalkynyl group optionally bearing one or more substituents selected from C1-12alkyl; C2-12alkenyl; C2-12alkynyl; C1-12heteroalkyl; C2-12heteroalkenyl; C2-12heteroalkynyl; C6-10aryl; C6-10heteroaryl; F; Cl; Br; I; —NO2; —CN; —CF3; —CH2CF3; CHCl2; or -GRA3 wherein G is —O—, —S—, —NRB3—, —(═O)—, —S(═O)—, —SO2—, —C(═O)O—, —C(═O)NRB3—, —OC(═O)—, —NRB3C(═O)—, wherein each occurrence of RA3 and RB3 independently represents hydrogen, or a C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12haloalkyl, C2-12haloalkenyl, C2-12haloalkynyl, C1-12heteroalkyl, C2-12heteroalkenyl or C2-12heteroalkynyl; and
R4 independently represents H, a cyclic or acyclic, substituted or unsubstituted, linear or branched C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12heteroalkyl, C2-12heteroalkenyl, C2-12heteroalkynyl, substituted or unsubstituted C6-10aryl or C4-10heteroaryl group; —ORA4; —C(═O)RA4; or —SRA4; wherein each occurrence of RA4 independently represents hydrogen or a cyclic or acyclic, substituted or unsubstituted, linear or branched C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12heteroalkyl, C2-12heteroalkenyl, C2-12heteroalkynyl, C6-10aryl or C4-10heteroaryl group; wherein each of the foregoing alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl or heteroaryl, group may optionally bear one or more substitutents selected from C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12heteroalkyl, C2-12heteroalkenyl, C2-12heteroalkynyl, C6-10aryl, C4-10heteroaryl, F; Cl; Br; I; —NO2; —CN; —CF3; —CH2CF3; CHCl2; or -GRB4 wherein G is —O—, —S—, —NRC4—, —(═O)—, —S(═O)—, —SO2—, —C(═O)O—, —C(═O)NRC4—, —OC(═O)—, —NRC4C(═O)—, wherein each occurrence of RB4 and RC4 independently represents independently represents hydrogen, or a C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12haloalkyl, C2-12haloalkenyl, C2-12haloalkynyl, C1-12heteroalkyl, C2-12heteroalkenyl, C2-12heteroalkynyl, C6-10aryl or C4-10heteroaryl group;
(ii) in the presence of at least one nucleophilic compound initiator and/or at least one base;
wherein the base and the nucleophilic compound initiator may be different compounds or one and the same compound; and
B) when R1 or R2 bears a protected form of at least one cationic moiety, the process further comprises at least one deprotection step of the protected form of the at least one cationic moiety to yield cationic peptoid/N-substituted peptidic copolymers; such as acidic or basic treatment.

### Claim 2 (depends on 1)

Process according to claim 1, for the preparation of linear peptoid/N-substituted peptidic copolymers, wherein the process is carried out in the presence of at least one nucleophilic compound initiator selected from primary amines, such as allylamine, n-hexylamine, n-decylamine, n-dodecylamine or n-octadecylamine.

### Claim 3 (depends on 1)

Process according to claim 1, for the preparation of macrocylic peptoid/N-substituted peptidic copolymers, wherein the process is carried out in the presence of at least a strong base selected from lithium, sodium or potassium amides, lithium, sodium or potassium hydrides, or phosphazenes.

### Claim 4 (depends on 3)

Process according to claim 3, wherein the strong base is a lithium amide, such as lithium bis(trimethylsilyl) amide.

### Claim 5 (depends on 1)

Process according to claim 1, for the preparation of dendritic peptoid/N-substituted peptidic copolymers, wherein the process is carried out in the presence of at least one dendritic synthon comprising at least three nucleophilic moieties selected from amino, thio or hydroxyl groups, and optionally at least one base selected from tertiary amines such as triethylamine or N, N-Diisopropylethylamine in particular when the at least one dendritic synthon comprises non-basic nucleophilic moieties selected from thio or hydroxyl groups.

### Claim 6 (depends on 5)

Process according to claim 5, wherein the at least one dendritic synthon is a PAMAM synthon having one of the following structures:

### Claim 7 (depends on 1)

Process according to claim 1, for the preparation of peptoid/N-substituted peptidic copolymer-drug conjugates, wherein the process is carried out in the presence of at least one drug molecule bearing at least one nucleophilic moiety, and optionally at least one base selected from tertiary amines such as trimethylamine or N, N Diisopropylethylamine.

### Claim 8 (depends on 7)

Process according to claim 7, wherein the at least one drug molecule bears at least one basic primary amino group, such as vancomycin, amoxicilline, kanamycine, cefaclor, amphotericin B, nystatin, amikacin or sulfamethoxazole; and the process is carried out without a tertiary amine.

### Claim 9 (depends on 1)

Process according to claim 1, wherein the first and second N-carboxyanhydride monomers have the structure
respectively;
wherein R1 represents an optionally protected cationic side chain of a natural or modified amino acid, and R3 represents an optionally protected hydrophobic side chain of a natural or modified amino acid.

### Claim 10 (depends on 1)

Process according to claim 1, wherein the first N-carboxyanhydride monomers has the structure
wherein R1 represents —C1-6alkyl-NHP1, wherein P1 represents an amine protecting group, such as —(C═O)OPh.

### Claim 11 (depends on 1)

Process according to claim 1, wherein the first and second N-carboxyanhydride monomers have the structure respectively,
wherein R1 represents an optionally protected cationic side chain of a natural or modified amino acid, and R3 represents an optionally protected hydrophobic side chain of a natural or modified amino acid.

### Claim 12 (depends on 1)

Process according to claim 1, wherein the first N-carboxyanhydride monomers has the structure
wherein R1 represents —C1-6alkyl-NHP1, wherein P1 represents an amine protecting group, such as —(C═O)OPh.

### Claim 13 (depends on 1)

Process according to claim 1, wherein the molar ratio first N-carboxyanhydride monomer:second N-carboxyanhydride monomer ranges between 0:100 and 100:0, preferably 50:50 and preferentially with cationic content higher than 50%.

### Claim 14 (depends on 1)

Process according to claim 1, wherein the polar organic solvent is an aprotic solvent such as DCM, DMF, Dioxane, DMSO, Benzonitrile, THF or a mixture thereof.

### Claim 15 (depends on 1)

Process according to claim 1, wherein the first or second N-carboxyanhydride monomer is prepared by a process comprising steps of:
(i) reacting an amine R—NH2 with a carboxylic acid having the structure R′(C═O)—CO2H to form an amino acid compound having the structure (III):
wherein
R represents R1 or R3 as defined in claim 1;
R′ represents R2 or R4 as defined in claim 1, preferably R′ represents H; and
M represents a hydrogen atom or an alkali metal cation selected from Na, Li or K;
(ii) reacting the compound of structure (III) with a nitrogen-protecting group under suitable conditions to form a protected amino acid compound having the structure (IV):
wherein P1 represents a suitable-amine protecting group, preferably P1 represents a Boc protecting group; and
(iii) effecting cyclization of compound (IV) under suitable conditions to form a N carboxyanhydride monomer having the structure:
wherein
R represents R1 or R3 as defined in claim 1; and R′ represents R2 or R4 as defined in claim 1, preferably R′ represents H.

### Claim 16 (depends on 15)

Process according to claim 15, wherein the resulting N-carboxyanhydride monomer has one of the flowing structures:

### Claim 17 (depends on 1)

Process according to claim 1, wherein the first or second N-carboxyanhydride monomer is prepared by a process comprising steps of:
(i) reacting a natural amino acid
with an amine protecting group, for example Boc2O or CbzCl, under suitable conditions to form a protected natural amino acid compound having the structure (V):
wherein
R′ represents R2 or R4 as defined in claim 1; and
P2 represents a carbamate protecting group, such as Boc or Cbz;
(ii) reacting the compound of structure (V) with a compound R—X under suitable conditions to form a compound having the structure (VI):
wherein
R represents R1 or R3 as defined in claim 1; and
X represents a suitable leaving group such as a sulfonate leaving group; and
(iii) effecting cyclization of compound (VI) under suitable conditions to form a N carboxyanhydride monomer having the structure:
wherein
R represents R1 or R3 as defined in claim 1; and R′ represents R2 or R4 as defined in claim 1.

### Claim 18 (depends on 17)

Process according to claim 17, wherein the resulting N-carboxyanhydride monomer has one of the flowing structures:

### Claim 19 (depends on 1)

Linear peptoid/N-substituted peptidic copolymer obtainable by a process of claim 1, wherein the linear peptoid/N-substituted peptidic copolymer has the following structure:
wherein R1, R2, R3 and R4 are as defined in claim 1;
Rinit represents the radical of a primary amine nucleophilic compound initiator, such as allyl, n-hexyl, n-decyl, n-dodecyl or n-octadecyl;
x ranges between 0 and 1, and represents the molar ratio of first N-carboxyanhydride monomer units in the copolymer;
y ranges between 0 and 1, and represents the molar ratio of second N-carboxyanhydride monomer units in the copolymer;
wherein x+y=1 and the x and y repeat monomer units are randomly distributed in the macrocyclic peptoid/N-substituted peptidic copolymer-; and
n represents the number of first and second N-carboxyanhydride monomer unit in the copolymer.

### Claim 20 (depends on 19)

Linear peptoid/N-substituted peptidic copolymer according to claim 19, wherein n is from 10 to 100, preferably from 20 to 80.

### Claim 21 (depends on 1)

Macrocylic peptoid/N-substituted peptidic copolymer obtainable by a process of and claim 1, wherein the macrocylic peptoid/N-substituted peptidic copolymer has the following structure:
wherein R1, R2, R3 and R4 are as defined in claim 1;
(Ra, Rb) may represent (R1, R2) or (R3, R4), respectively;
independently of (Ra, Rb), (Rc, Rd) may represent (R1, R2) or (R3, R4), respectively;
M+ represents a counterion, such as H+, Li+, Na+, K+ or an alkali metal salt such as LiHMDS;
x ranges between 0 and 1, and represents the molar ratio of first N-carboxyanhydride monomer units in the copolymer;
y ranges between 0 and 1, and represents the molar ratio of second N-carboxyanhydride monomer units in the copolymer;
wherein x+y=1 and the x and y repeat monomer units are randomly distributed in the macrocyclic peptoid/N-substituted peptidic copolymer-; and
n represents the number of first and second N-carboxyanhydride monomer unit in the copolymer chain.

### Claim 22 (depends on 21)

Macrocylic peptoid/N-substituted peptidic copolymer according to claim 21, wherein n is from 10 to 100, preferably from 20 to 80.

### Claim 23 (depends on 21)

Macrocylic peptoid/N-substituted peptidic copolymer according to claim 21, wherein R1 and R3 are different.

### Claim 24 (depends on 21)

Macrocylic peptoid/N-substituted peptidic copolymer according to claim 21, wherein R2 and R4 are each a hydrogen atom.

### Claim 25 (depends on 21)

Macrocylic peptoid/N-substituted peptidic copolymer according to claim 21, wherein R2 and R4 are each a hydrogen atom;
R1 represents a linear or branched C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12heteroalkyl, C2-12heteroalkenyl or C2-12heteroalkynyl group bearing an NH3+ moiety; such as —(CH2)4—NH3+ (the cationic form of a lysine residue side-chain); and
R3 represents a hydrophobic cyclic or acyclic, substituted or unsubstituted, linear or branched C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12heteroalkyl, C2-12heteroalkenyl, C2-12heteroalkynyl, substituted or unsubstituted C6-10aryl or C4-10heteroaryl group; each of the foregoing alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl or heteroaryl group; such as the —CH2Ph side-chain of a phenylalanine residue.

### Claim 26 (depends on 1)

Dendritic peptoid/N-substituted peptidic copolymer obtainable by a process of claim 1, wherein the dendritic peptoid/N-substituted peptidic copolymer has the following structure:
wherein R1, R2, R3 and R4 are as defined in claim 1;
Rdend represents a dendritic synthon radical having one of the following structures:
x ranges between 0 and 1, and represents the molar ratio of first N-carboxyanhydride monomer units in the copolymer;
y ranges between 0 and 1, and represents the molar ratio of second N-carboxyanhydride monomer units in the copolymer;
wherein x+y=1 and the x and y repeat monomer units are randomly distributed in the macrocyclic peptoid/N-substituted peptidic copolymer-;
each occurrence of n independently represents the number of first and second N carboxyanhydride monomer units in the copolymer branch; and
m represents the number of copolymer units covalently bound to the dendrimer synthon.

### Claim 27

Dendritic peptoid/N-substituted peptidic copolymer, wherein n is from 10 to 100, preferably from 20 to 80.

### Claim 28 (depends on 1)

Peptoid/N-substituted peptidic copolymer-drug conjugate obtainable by a process of claim 1, wherein the peptoid/N-substituted peptidic copolymer-drug conjugate has the following structure:
wherein R1, R2, R3 and R4 are as defined in claim 1;
Rdrug represents the radical of a drug molecule bearing at least one basic primary amino group, such as vancomycin, amoxicilline, kanamycine, cefaclor, amphotericin B, nystatin, amikacin or sulphamethoxazole;
x ranges between 0 and 1, and represents the molar ratio of first N-carboxyanhydride monomer units in the copolymer;
y ranges between 0 and 1, and represents the molar ratio of second N-carboxyanhydride monomer units in the copolymer;
wherein x+y=1 and the x and y repeat monomer units are randomly distributed in the macrocyclic peptoid/N-substituted peptidic copolymer-;
each occurrence of n independently the number of first and second N-carboxyanhydride monomer unit in the copolymer-; and
m represents the number of copolymer units covalently bound to the drug molecule.

### Claim 29

Peptoid/N-substituted peptidic copolymer-drug conjugate, wherein n is from 10 to 100, preferably from 20 to 80.

### Claim 30 (depends on 28)

Peptoid/N-substituted peptidic copolymer-drug conjugate according to claim 28, the group Rdrug in formula (Vconj) may have one of the following structures, wherein the arrows designate the point(s) of attachment of the N-substituted copolymer to the group Rdrug:

### Claim 31 (depends on 1)

Peptoid/N-substituted peptidic copolymer obtainable by a process according to claim 1, wherein the peptoid/N-substituted peptidic copolymer is resistant to peptidases in aqueous medium.

### Claim 32 (depends on 1)

Peptoid/N-substituted peptidic copolymer obtainable by a process according to claim 1, wherein the peptoid/N-substituted peptidic copolymer is effective at killing bacteria.

### Claim 33 (depends on 1)

Peptoid/N-substituted peptidic copolymer obtainable by a process according to claim 1, wherein the peptoid/N-substituted peptidic copolymer mimicks the antimicrobial activity of antimicrobial peptides against Clostridioides difficile, S. aureus meti-S, S. aureus meti-R, Streptococcus pneumoniae, Listeria monocytogenes, Enterococcus faecalis, Escherichia coli, Acinetobacter baumanii, Pseudomonas aeruginosa, Bacteroides fragilis, and/or Helicobacter pylori.

### Claim 34 (depends on 1)

Pharmaceutical composition comprising an effective amount of a peptoid/N-substituted peptidic copolymer obtainable by a process according to claim 1 or pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 35 (depends on 30)

The pharmaceutical composition of claim 30, wherein the composition is formulated to be coated on the surface of an implantable medical device.

### Claim 36 (depends on 1)

Peptoid/N-substituted peptidic copolymer obtainable by a process according to claim 1 or pharmaceutically acceptable derivative thereof, for use as antimicrobial agent.

### Claim 37 (depends on 30)

An item impregnated with or coated with the composition of claim 30, wherein the item is selected from the group consisting of a medical device, medical instrument, medical implement, prosthetic, implantable device or material or tissue and wound dressing.
